Date | Time | Source | Headline | Symbol | Company |
06/13/2024 | 7:58AM | PR Newswire (US) | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | NASDAQ:PAVM | PAVmed Inc |
06/12/2024 | 8:05AM | PR Newswire (US) | 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing | NASDAQ:PAVM | PAVmed Inc |
05/13/2024 | 8:43PM | PR Newswire (US) | PAVmed Provides Business Update and First Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
05/13/2024 | 8:00AM | PR Newswire (US) | Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results | NASDAQ:PAVM | PAVmed Inc |
05/09/2024 | 7:49AM | PR Newswire (US) | Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall | NASDAQ:PAVM | PAVmed Inc |
05/07/2024 | 7:39AM | PR Newswire (US) | Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors | NASDAQ:PAVM | PAVmed Inc |
05/03/2024 | 8:35AM | PR Newswire (US) | PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 | NASDAQ:PAVM | PAVmed Inc |
05/02/2024 | 8:35AM | PR Newswire (US) | Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 | NASDAQ:PAVM | PAVmed Inc |
05/02/2024 | 7:49AM | PR Newswire (US) | Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing | NASDAQ:PAVM | PAVmed Inc |
04/30/2024 | 7:35AM | PR Newswire (US) | PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | NASDAQ:PAVM | PAVmed Inc |
04/29/2024 | 8:47AM | PR Newswire (US) | Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month | NASDAQ:PAVM | PAVmed Inc |
04/08/2024 | 8:30AM | PR Newswire (US) | Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:PAVM | PAVmed Inc |
03/26/2024 | 7:32PM | PR Newswire (US) | PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:PAVM | PAVmed Inc |
03/21/2024 | 9:30AM | PR Newswire (US) | Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population | NASDAQ:PAVM | PAVmed Inc |
03/21/2024 | 8:30AM | PR Newswire (US) | PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX | NASDAQ:PAVM | PAVmed Inc |
03/20/2024 | 8:30AM | PR Newswire (US) | Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference | NASDAQ:PAVM | PAVmed Inc |
03/13/2024 | 8:30AM | PR Newswire (US) | PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 | NASDAQ:PAVM | PAVmed Inc |
03/12/2024 | 8:30AM | PR Newswire (US) | Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024 | NASDAQ:PAVM | PAVmed Inc |
03/08/2024 | 4:30PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PAVM | PAVmed Inc |
02/23/2024 | 4:49PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PAVM | PAVmed Inc |
02/23/2024 | 4:46PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PAVM | PAVmed Inc |
02/23/2024 | 4:43PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PAVM | PAVmed Inc |
02/23/2024 | 4:41PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PAVM | PAVmed Inc |
02/20/2024 | 4:49PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:PAVM | PAVmed Inc |
02/20/2024 | 4:45PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:PAVM | PAVmed Inc |
02/16/2024 | 5:00PM | PR Newswire (US) | Lucid Diagnostics Provides Update Regarding World Trade Center Health Program | NASDAQ:PAVM | PAVmed Inc |
02/15/2024 | 7:45AM | PR Newswire (US) | Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony | NASDAQ:PAVM | PAVmed Inc |
02/14/2024 | 3:38PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:PAVM | PAVmed Inc |
02/09/2024 | 4:30PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:PAVM | PAVmed Inc |
02/08/2024 | 7:45AM | PR Newswire (US) | Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors | NASDAQ:PAVM | PAVmed Inc |